M.D., Ph.D., Founder & CEO, iSpecimen
Chris conceptualized and founded iSpecimen to address the growing need for human biospecimens by the life science research community. He is responsible for the company’s growth, performance, corporate direction and many of the new strategic partnerships. Prior to launching iSpecimen, Chris served as Managing Director at Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. Chris was also a co-founder of Health Insight Technologies (now Humedica), a novel healthcare informatics company. Prior to this, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors (BMSA), a healthcare investment research firm acquired by Leerink Swann. He received both his PhD in Immunology and his MD from Tufts University and completed his residency training in Pathology at Brigham & Women’s Hospital and Harvard Medical School.
Finding Patients and Specimens to Drive Precision Research
In the quest for evermore targeted care, the research we conduct must be just as precise as the medicine we envision. Scientists must gain easy access to the specimens and data they need from the patients they want. Learn how precision research is being accomplished on a large scale.
Session Synopsis: The demand for high quality biosamples poses a unique challenge to the advancement of Precision -omics based research. This session will evaluate the complexities involved in managing longitudinal studies with an emphasis on biosample quality, logistics, kit management, site training, sample management, consent management, and data management. When done well, large longitudinal Cohort Studies stand to provide an increasingly significant portion of the supply to support the increase in -omics based research